Sagimet Bioscience a Aktie
WKN DE: A3CPAM / ISIN: US7867001049
|
30.09.2026 13:04:56
|
Sagimet Reports Positive 52-Week Data For Denifanstat In Acne
(RTTNews) - Wednesday, Sagimet Biosciences (SGMT) reported positive 52-week results from a Phase 3 open-label extension study of denifanstat in patients with moderate to severe acne vulgaris, presented at EADV 2026.
Denifanstat is an oral, once-daily fatty acid synthase (FASN) inhibitor being developed for the treatment of moderate to severe acne.
After 52 weeks, denifanstat showed a 57% treatment success rate, along with a 72% reduction in total lesions and a 77% reduction in inflammatory lesions. The treatment was generally well tolerated, with no permanent discontinuations due to adverse events.
Sagimet said patient screening for its U.S. Phase 3 AURORA trial is expected to begin in October 2026.
Sagimetshares closed on Tuesday at $9.33, down 6.14%.
In the Premarket trading, shares are up 7.18% at $10.00.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sagimet Biosciences Inc Registered Shs -A-
| Keine Nachrichten verfügbar. |
Analysen zu Sagimet Biosciences Inc Registered Shs -A-
Aktien in diesem Artikel
| Sagimet Biosciences Inc Registered Shs -A- | 9,16 | -1,08% |
|